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Abstract
Growing evidence from both epidemiology and basic science suggest an inverse association 
between Alzheimer’s disease (AD) and cancer. We examined the genetic relationship between AD 
and various cancer types using GWAS summary statistics from the IGAP and GAME-ON 
consortia. Sample size ranged from 9,931 to 54,162; SNPs were imputed to the 1000 Genomes 
European panel. Our results based on cross-trait LD Score regression showed a significant positive 
genetic correlation between AD and five cancers combined (colon, breast, prostate, ovarian, lung; 
rg = 0.17, P = 0.04), and specifically with breast cancer (ER-negative and overall; rg = 0.21 and 
0.18, P = 0.035 and 0.034) and lung cancer (adenocarcinoma, squamous cell carcinoma and 
overall; rg = 0.31, 0.38 and 0.30, P = 0.029, 0.016, and 0.006). Estimating the genetic correlation 
in specific functional categories revealed mixed positive and negative signals, notably stronger at 
annotations associated with increased enhancer activity. This suggests a role of gene expression 
regulators in the shared genetic etiology between AD and cancer, and that some shared variants 
modulate disease risk concordantly while others have effects in opposite directions. Due to power 
issues, we did not detect cross-phenotype associations at individual SNPs. This genetic overlap is 
not likely driven by a handful of major loci. Our study is the first to examine the co-heritability of 
AD and cancer leveraging large-scale GWAS results. The functional categories highlighted in this 
study need further investigation to illustrate the details of the genetic sharing and to bridge 
between different levels of associations.
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Introduction
Alzheimer’s disease (AD) and cancer are complex diseases of aging that impose an 
enormous public health burden worldwide (Brookmeyer et al. 2007; Lopez et al. 2006; Thun 
et al. 2010). There is a growing understanding that these seemingly disparate conditions 
have substantial overlap. The pathophysiology of AD includes most if not all of the 
hallmarks of cancer, including abnormal cell cycle entry, metabolic deregulation, oxidative 
stress, DNA damage, inflammation, and angiogenesis (Hanahan and Weinberg 2011). All of 
these similarities suggest the diseases would be comorbid, but the weight of epidemiological 
evidence points to an unusual inverse association (Catala-Lopez et al.; Driver et al. 2012; 
Musicco et al. 2013; Realmuto et al. 2012; Roe et al. 2005; Roe et al. 2010).
While it is difficult to know for sure that this “inverse comorbidity” represents a true 
association and is not the result of survival bias, there is convincing biological evidence for 
it. A transcriptomic meta-analyses using gene-expression data from relevant tissues found a 
substantial number of shared genes and their corresponding pathways to be upregulated in 
AD but downregulated in lung, colorectal and prostate cancers, and vice versa (Ibanez et al. 
2014). Differential expression of microRNAs between cancer and Alzheimer’s disease has 
also been demonstrated (Holohan et al. 2012). A number of shared proteins and pathways 
have been identified that are differentially regulated by cancer cells and degenerating 
neurons. This includes the enzyme Pin, which is overexpressed in most cancers but depleted 
in AD (Bao et al. 2004); tumor suppressor p53, which promotes apoptosis but protects 
against cancer (van Heemst et al. 2005); and the Wnt cell survival pathway, which is 
activated in cancer but downregulated in AD (Inestrosa and Toledo 2008). Genetics play an 
important role in these underlying biological pathways, and therefore is expected to 
contribute to the inverse relationship between the two disorders either additively or through 
interaction with external factors (Demetrius and Simon 2013; Ibanez et al. 2014; Tabares-
Seisdedos and Rubenstein 2013).
However, beyond these three long-suspected but yet-to-be-confirmed candidates (Pin1, p53 
and Wnt), very little is known about the genetic overlap between AD and cancer. Using 
genome-wide association study (GWAS) individual level data or summary statistics, one 
might be able to identify significant single nucleotide polymorphisms (SNPs) common to 
both disorders and estimate the cross-trait heritability. Existing methods based on genotype 
data, such as bivariate restricted maximum likelihood estimation (REML) as implemented in 
Genome-wide Complex Trait Analysis (GCTA) (Lee et al. 2012; Yang et al. 2011) and 
genetic risk score profiling (Cross-Disorder Group of the Psychiatric Genomics 2013; 
Purcell et al. 2009), have been applied to a number of traits for estimating genetic 
correlations. Another approach is LD Score regression of summary statistics, as was recently 
applied to 24 traits to assess their pairwise genetic correlations (Bulik-Sullivan et al. 2015a). 
Patterns of genetic overlap among 42 traits were also examined using a Bayesian approach 
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(Pickrell et al. 2016). No study has yet reported the genetic correlation between cancer and 
AD.
In the present study, we investigated the genetic overlap between AD and a variety of cancer 
types using SNP-trait GWAS summary statistics. We first estimated the genome-wide 
genetic correlation between the two diseases, then evaluated sharing heritability in specific 
functional categories, and finally tested cross-disease associations at individual SNPs. We 
used AD GWAS meta-analysis summary-level data acquired from the International 
Genomics of Alzheimer’s Project (IGAP) and nine cancer GWAS meta-analysis results from 
the Genetic Associations and Mechanisms in Oncology (GAME-ON) consortium. There 
were 54,162 individuals included in the IGAP dataset and a sample size ranging from 9,931 
to 33,832 among the GAME-ON datasets. All were imputed with over 7 million SNPs from 
the 1000 Genomes Project. This to our knowledge is the first study to investigate the genetic 
overlap between AD and specific cancer types using large-scale GWAS summary results 
where no individual genotype data is required.
Materials and Methods
Data: GWAS summary statistics for AD and each cancer type
Summary statistics of association analysis for late-onset AD were obtained from the 
International Genomics of Alzheimer’s Project (IGAP; (Lambert et al. 2013)), available 
upon request. International Genomics of Alzheimer’s Project (IGAP) is a large two-stage 
study based upon genome-wide association studies (GWAS) on individuals of European 
ancestry. In stage 1, IGAP used genotyped and imputed data on 7,055,881 single nucleotide 
polymorphisms (SNPs) to meta-analyse four previously-published GWAS datasets 
consisting of 17,008 Alzheimer’s disease cases and 37,154 controls (The European 
Alzheimer’s disease Initiative – EADI, the Alzheimer Disease Genetics Consortium – 
ADGC, The Cohorts for Heart and Aging Research in Genomic Epidemiology consortium – 
CHARGE, The Genetic and Environmental Risk in AD consortium – GERAD; Table 1). 
European population reference haplotype data in the 1000 Genomes Project (2010 release) 
was used for genotype imputation, and genomic control correction was applied to each study 
before meta-analysis. In stage 2, 11,632 SNPs were genotyped and tested for association in 
an independent set of 8,572 Alzheimer’s disease cases and 11,312 controls. Finally, a meta-
analysis was performed combining results from stages 1 & 2.
Summary statistics for cancers were acquired from the Genetic Associations and 
Mechanisms in Oncology (GAME-ON) consortium, which included meta-analysis results 
for nine cancer types (colon cancer, ER-negative breast cancer, overall breast cancer, 
aggressive prostate cancer, overall prostate cancer, ovarian cancer, lung adenocarcinoma, 
lung squamous cell carcinoma, and overall lung cancer (Table 1). Study designs included 
population-based, hospital-based, or family-based case-control studies. SNPs in individual 
studies were genotyped using Affymetrix or Illumina platform, and SNP imputation was 
performed using IMPUTE2, MiniMAC or MACH with 1000 Genomes Project (March 2012) 
data as reference. In each study, principle components were adjusted in association analysis 
to control for confounding by population stratification. Imputed SNPs were filtered 
according to imputation quality (r2) before meta-analysis, which was implemented using 
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METAL (Willer et al. 2010). The final number of SNPs ranged from 9M to 15M across 
cancer types, the number of samples also varied to some extent, with colon cancer and 
ovarian cancers having a smaller number (~10K–13K) while prostate, breast, and lung 
cancers having a larger number of samples (~20K–30K).
Study subjects in IGAP and GAME-ON were all of European ancestry and originated from 
countries in Europe, Canada, the United States, or Australia. There is no sample sharing 
between AD and any of the cancer studies used in our analysis.
Estimation of genome-wide genetic correlation
Genetic correlation between AD and each cancer type was estimated by cross-trait LD Score 
regression (Bulik-Sullivan et al. 2015a). This is a recently developed method based on 
GWAS summary statistics that quantifies the genetic covariance (ρg; analogous to co-
heritability) between two traits by regressing the product of the z-scores (Z1jZ2j) from two 
studies of traits against the LD Score (lj) for each SNP j, assuming both traits follow 
polygenic inheritance. Genetic correlations were obtained as  by 
normalizing genetic covariance by SNP-heritability  for each trait estimated from 
single-trait LD Score regression (Bulik-Sullivan et al. 2015b). AD and cancer as complex 
diseases likely possess a polygenic genetic architecture and therefore it is appropriate for 
using cross-trait LD score regression to estimate their genetic correlation. Empirical genetic 
correlations between AD and cancer were also calculated by taking Pearson’s correlation 
coefficients of AD z-score and cancer z-score from all SNP to get an initial sense of the 
direction and magnitude of the genetic parameter and to be compared with the rg estimates 
from LD Score regression.
The analysis was implemented using the LDSC v1.0.0 software package (Bulik-Sullivan et 
al. 2015b). First, LD scores of all SNPs from individuals of European descent in the 1000 
Genomes Project were computed. Next, genetic correlation of each cancer type with AD was 
estimated via cross-trait LD Score regression. Only IGAP stage1 data was used in the 
following analysis, because LDSC is designed for genome-wide analysis with SNPs 
scattered across the genome and does not work well for a concentrated set of SNPs showing 
significant association with a trait of interest. Intercepts from cross-trait LD Score regression 
were constrained to zeros as there is no sample overlap. The number of overlapping SNPs 
between AD and each cancer dataset was around 5M to 6M. Before investigating the 
genome-wide relationship of AD with individual cancer types, we examined the genetic 
correlation between AD and “any cancer type” combined using five independent GAME-ON 
cancer data sets that do not share samples with one another, including that of colon cancer, 
overall breast cancer, overall prostate cancer, ovarian cancer, and overall lung cancer. The 
summary association statistics for “any cancer” were obtained by meta-analyzing GWAS 
summary statistics data from the five cancer types using METAL (Willer et al. 2010).
Estimation of annotation-specific genetic correlation
To characterize the genetic overlap at the level of functional categories, for each cancer type 
that showed significant genetic sharing with AD, we estimated genetic correlation between 
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AD and cancer in eight large annotations using cross-trait LD score regression. These 
annotations included repressed region, introns, transcribed region, super enhancers, DNase I 
hypersensitivity sites (DHSs), and histone marks H3K27ac, H3K4me1, and H3K4me3 
(Finucane et al. 2015; Gusev et al. 2014). Each of them contained more than 600,000 
overlapping SNPs between the AD and cancer datasets that appropriates the use of LD score 
regression. For each annotation, we re-calculated LD scores for SNPs assigned to that 
particular category and then used the annotation-specific LD scores for estimating the AD-
cancer genetic correlation.
Detection of individual SNPs associated with AD and cancers
Tests for cross-phenotype effects were carried out at individual loci to detect SNPs that show 
cross-phenotype (CP) associations with both AD and cancer, for the cancer types that have a 
significant genetic correlation with AD.
For each cancer type, among the SNPs overlapping between AD and cancer summary 
statistics, we started by picking out SNPs with a less stringent p-value cutoff at SNP-AD p-
value < 0.001, then selecting SNPs every 100kb apart to mimic LD pruning and to 
appropriately evaluate statistical significance based on number of independent tests; SNPs 
selected within each window were those with the smallest SNP-AD p-values. Next, we 
looked for any additional signal from cancer beyond the existing SNP-AD association. 
Bonferroni correction was used to correct for multiple testing.
To search for SNPs of a possible CP effect on AD and one or more cancer types, we also 
conducted individual SNP meta-analysis using Cross-Phenotype Meta-Analysis (CPMA; 
(Cotsapas et al. 2011)) to explore if there is any SNP associated with some of the cancer 
types in addition to its correlation with AD. The filtered SNPs with a SNP-AD p-value < 
0.001 again underwent distance pruning based on a window of 100kb. CPMA was 
performed among the remaining SNPs, followed by FDR control to correct for multiple 
testing. SNPs were assigned to genes via PLINK with SNP attributes--dbSNP build 129 and 
gene range list--hg19 for inference of a potential common biological process between the 
two traits. eQTL function for each top SNP was checked upon at the Genotype-Tissue 
Expression (GTEx) portal.
Results
Genetic correlation estimates between AD and cancer
We observed an overall positive genetic correlation of 0.172 between AD and the five 
cancers combined (colon, breast cancer, prostate, ovarian, and lung cancers; p-value = 0.04) 
estimated via cross-trait LD Score regression from the 6 million SNPs included in both 
GWASs (Table 2; fig. 1).
Stratifying by cancer type, ER-negative and overall breast cancer showed significant positive 
genetic correlations with AD at rg = 0.21 (p-value = 0.04) and rg = 0.18 (p-value = 0.03), 
respectively. Lung adenocarcinoma, lung squamous cell carcinoma, and overall lung cancer 
also had a prominent positive genetic correlation with AD at rg = 0.31 (p-value = 0.03), 0.38 
(p-value = 0.02), and 0.30 (p-value = 0.01). This implied that the two traits—AD and breast 
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cancer, or AD and lung cancer—may share some common genetic background across the 
genome and the shared gene variants modulate the diseases risk in the same direction. On 
the contrary, the genetic correlation between AD and aggressive and overall prostate cancer 
were negative but not statistically significant (rg = −0.07 and −0.09; p-value = 0.54 and 0.20, 
respectively). The genetic correlation was around 0.1 between AD and all colon cancer and 
was slightly below zero between AD and ovarian cancer, and both estimates were not 
significant. These two cancer types also had the smallest sample size and might be 
underpowered for detecting genetic correlation.
The genetic correlation estimates from cross-trait LD Score regression were consistent in 
terms of direction, relative magnitude, and statistical significance with our initial inspection 
of empirical correlation estimates between AD and each cancer type calculated as the 
Pearson’s correlation coefficients between z-scores for all SNPs from the two traits (Online 
Resource Table S1), when LD between SNPs were not taken into account.
After learning the genome-wide relationship between AD and a variety of cancer types, we 
attempted to characterize the genetic sharing at regional and at individual SNP level between 
AD and the 2 cancer types that have a significant signal of genetic correlation, i.e. breast and 
lung cancers (overall).
Genetic correlation between AD and cancer by functional category
The first approach was evaluating the genetic correlation between AD and cancers by 
functional annotations to pin down specific regions on the genome that may explain more of 
the genetic sharing than others. This analysis additionally evaluated the annotation-specific 
relationship between AD and “any cancer type” where a notable positive rg was also 
observed.
Our results showed that annotation-specific genetic correlations were comprised of a mixture 
of positive and negative signals (Figure 2; Table S2). Effect sizes of genetic variants in the 
repressed and the H3K4me3 annotations were negatively correlated between AD and breast 
cancer, lung cancer or the “any cancer” category, whereas positive genetic correlations were 
observed in the other six annotations. The only significant relationship between AD and the 
five cancer types combined appeared at super enhancers. Examining across all functional 
categories, three regions that represent active enhancer marks on the genome, including 
super enhancers, H3K27ac, and H3K4me1, all showed stronger and positive AD-cancer 
genetic correlations. This indicated a possible role of gene expression regulation with 
respect to enhancer activity in the shared genetic etiology of AD and cancer.
Cross-phenotype associations between AD and cancer
In order to investigate if cross-trait genetic correlation could be explained by major genetic 
loci, we went down to individual locus level to find pleiotropic SNPs associated with both 
AD and cancer, the existence of which may implicate common genetic pathways shared by 
the two diseases.
For each cancer type, we searched for any AD-related SNPs that also have an effect on 
cancer. A total of 11,788 out of the 4,743,056 SNPs common in both AD and breast cancer 
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summary statistics and 14,655 out of the 5,681,315 AD-lung cancer overlapping SNPs 
remained after the filtering procedure (SNP-AD p-value < 0.001). There were 1507 SNPs 
present in both AD and breast cancer and 1648 SNPs present in both AD and lung cancer 
datasets after the 100kb window based pruning of SNPs. Among them, no SNP was 
significant after Bonferroni correction for breast cancer (top SNP rs59776273; 
chr4:47,792,047, SNP-breast cancer p-value = 9.9*10−5). While for lung cancer there were 
two candidate SNPs that survived the correction: rs56117933 at chr15:78,832,349 
(unadjusted SNP-lung cancer p-value = 4.1*10−20, corrected p-value = 6.7*10−17; AD z-
score = −3.34, lung cancer z-score = 9.19), in close proximity to the PSMA4 gene encoding 
for proteasome subunit alpha 4, whose polymorphisms have been related to lung cancer 
susceptibility from published GWAS (Hung et al. 2008), and rs11249708 at chr5: 
179821728 (unadjusted SNP-lung cancer p-value = 1.5*10−5, corrected p-value = 0.025; AD 
z-score = −3.43, lung cancer z-score = 4.33), for which no previous genome-wise 
associations have been reported.
We next carried out CPMA tests to find SNPs showing residual association with one or both 
cancer types, given its initial association with AD at SNP-AD p-value < 0.001. The results 
showed that, 11 out of 1458 SNPs after distance pruning had a CPMA p-value < 0.01, but 
only one of them passed the FDR 5% threshold (Table 3). This top SNP rs56117933 (CPMA 
p-value < 2.2*10−16; AD z-score = −3.34, breast cancer z-score = −0.59, lung cancer z-score 
= 9.19) was the same as discovered just previously, which had a highly significant 
association with lung cancer (p-value = 4.1*10−20) but a much larger p-value with breast 
cancer (>0.05). The significant AD SNP showing additional association with cancers was 
likely driven by one cancer type, similarly for the other 10 SNPs. This might reflect the 
heterogeneous nature of different cancer types and suggested to look for CP effects on AD 
and cancer independently by cancer type. The results also showed that cross-trait genetic 
relationships observed at the genome-wide level was not likely explained by several major 
variants, consistent with the polygenic architecture. Significant positive genetic correlations 
were found for between AD-breast cancer and AD-lung cancer, but as expected the SNP-AD 
z-score and the SNP-cancer z-score were not necessarily in the same direction. For example, 
SNP rs17466060 appeared to increase AD risk (z-score = 4.60) but decrease the risk of both 
breast cancer (z-score = −2.39) and lung cancer (z-score = −3.45). No significant eQTLs 
were found for the 11 SNPs in the most relevant tissues (brain or tumor) from the GTEx 
project, nor did they correspond to genetic variants on the previously reported candidate 
genes encoding p53, Pin1, or those involving in the Wnt pathway. The CP results on 
individual SNPs suggest that it would need a much larger sample size to obtain the same 
power as the cross-trait heritability estimate which aggregated information from all available 
SNPs on the genome or a particular functional category, and allow us to study the sharing 
genetic architecture of two diseases.
Discussion
In this study using data from two large GWAS consortia, we found a significant positive 
genetic correlation between AD and cancer overall, and specifically with breast and lung 
cancer. We also observed a suspected negative genetic correlation between AD and prostate 
cancer. These results establish that there is shared genetic variation between AD and cancer, 
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but suggests that the direction of the genome-wide association may differ by cancer type. 
Examining the genetic correlation between AD and each cancer type in specific functional 
categories revealed that annotations linked to enhancer activity could play a role in the 
genetic sharing between the two diseases. These annotations may harbor important genetic 
variants involved in common pathophysiological pathways. Although we did not find 
pleotropic or cross-phenotype SNPs, our study might not be well-powered enough to detect 
the associations at individual loci.
As we went from genome-wide investigation to a more local analysis of genetic relationship, 
we observed mixed signals of positive and negative directions of shared genetic effect within 
specific annotations. We also noted a discordance in effect size and direction across AD and 
cancers at the level of individual SNPs. This is expected, and confirmed that the overall 
aggregated genetic correlation is a sum of positive and negative genetic correlations due to 
different functional regions or individual variants. The power to detect shared genetic 
architecture at whole-genome, whole-functional category would be dependent on the 
consistency of effect direction of genetic variants in those categories or even the whole 
genome.
Before interpreting the results of genetic correlation, it is important to acknowledge the 
possibility of confounding due to an imbalanced proportion of cancer survivors in AD cases 
vs. controls. If there were more cancer survivors among the AD patients than controls, 
genetic correlation analysis might pick up some cancer associations from cancer-related 
SNPs, resulting in a larger genetic overlap between AD and cancer than by chance, and 
contributing to an inflated positive genetic correlation. Unfortunately, we could not obtain 
information on cancer history from each study in order to directly examine the impact of 
cancer survivorship on our estimation. However, a study based on the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) cohort, one of the studies included in the ADGC of IGAP, 
suggested that the proportion of subjects with a history of cancer incidence in the study was 
around 31% (sample size = 1609), and those with AD at baseline were less likely to be 
cancer survivors than participants with mild cognitive impairment, subjective memory 
complaints and normal cognition (Nudelman et al. 2014).
Another possible confounder is the ratio of different cancer types in individual AD studies, 
as the genetic association between AD and cancer likely differs by cancer type. Non-lethal 
cancer (such as non-melamona skin cancer) and cancers that are screened for and cured 
(such as breast, prostate and colon) would be the most prevalent in an older population. In 
contrast, highly lethal cancers such as lung and pancreas, would have a lower prevalence and 
thus be less likely to act as a confounder. This indicates that our findings for lung cancer and 
aggressive subgroups of breast and prostate cancer might be more credible than the other 
analyses. Another situation when this bias would be less of a concern is when cases and 
controls are matched based on cancer history. Although in the present study we could not 
rule out the possibility of the potential confounding discussed herein, we suggest that future 
work report genetic correlations considering the effects of differential cancer survivor rates 
among AD cases and controls whenever this information is attainable. For example, one can 
conduct a sensitivity analysis excluding studies in which AD patients and controls have a 
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dissimilar proportion of cancer survivors to evaluate the change in the estimates of genetic 
correlation.
Our study found overall positive genetic correlations between AD and breast cancer and 
lung cancer, while epidemiological studies (Catala-Lopez et al.; Driver et al. 2012; Musicco 
et al. 2013) and a transcriptome meta-analysis (Ibanez et al. 2014) suggest an overall inverse 
association of AD with many cancer types. This might be due to the fact that phenotypic 
comorbidity, correlation of expression effect and correlation of genetic effect are different 
levels of association that should not be expected to be the same. The inverse comorbidity of 
two diseases could be due to the joint effect of genetics and environment, where the non-
genetic effect could be negatively correlated and have a larger magnitude than the positively 
correlated genetic effect. In the context of survival bias, particularly for lung cancer, despite 
an inverse association at the phenotypic level, there might be a subset of individuals who are 
susceptible to both AD and lung cancer that is the driving force for the observed positive 
genetic correlation. A possible scenario in which a negative AD-cancer association based on 
differential gene expression in relevant tissues (Ibanez et al. 2014) can co-exist with a 
positive genetic correlation among SNPs is depicted in Fig. 3a; we note that this is only one 
of the numerous possibilities. In this case, the risk allele of a given SNP is associated with a 
decrease in expression of gene A in tissue 1 (eg. brain tissue) but an increase in its 
expression in tissue 2 (eg. tumor tissue). An increased expression of gene A in tissue 1 is 
associated with a reduced risk of AD, while its higher expression in tissue 2 is associated 
with an elevated risk of cancer, resulting in inverse molecular comorbidity. This level of 
association can in fact be bi-directional. The net SNP effects on the two diseases would be 
positive (βSNP=&beta;1&beta;2), and lead to a positive rg if the same is true for many more 
SNPs. In the analysis of partitioned co-heritability by functional categories, we observed 
both positive and negative genetic correlation in different categories. The functional 
annotation related to the negatively correlated category might explain the negatively 
correlated expression-AD association reported in previous studies and warrant further 
functional experiment.
Given the significant genome-wide associations of AD with some cancer types we have 
identified, we would need to gather gene expression data from brain and tumor tissues to 
establish a causal relationship linking SNP, gene expression, and both phenotypes together. 
Some possible scenarios for this are shown in Fig. 3b. This would ideally be accomplished 
in eQTL studies that can evaluate which SNPs have a direct effect on the phenotypes, which 
SNPs have an indirect effect mediated by gene expression, how those SNPs affect or 
regulate gene expression levels to exert their influences on the phenotypes, and what genes 
are being regulated. eQTLs might also have different effect directions in tissues relevant to 
AD and tissues relevant to cancers. Integration of these results with other –omics data (e.g. 
Methylation QTL) would help to better understand the underlying molecular mechanism of 
shared genetics and how that could lead to the suggested AD-cancer comorbidity, thereby 
allowing definition of a more accurate link between the phenotypic association and the 
genetic association of AD with cancer.
In addition, we noticed that most of our genetic correlation estimates were of small 
magnitude and have a relatively large standard error (SE). This is likely due to sample size 
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and from using summary level GWAS data instead of genotype data. It has been shown that 
genetic correlation in bivariate analysis (rg) as a genetic parameter has a much larger 
sampling variance compared to proportion of phenotypic variance explained (hg2) by all 
SNPs in univariate analysis, which is true for both individual genotype data and in a 
pedigree design (Visscher et al. 2014). Simulation also showed that, when analyzing two 
case-controls studies of independent samples with an equal hg2 = 0.2 using genotype data, 
the power to detect an rg = 0.4 with a sample size of 10,000 for each study is 0.9 and is only 
0.4 when rg = 0.2 (Visscher et al. 2014). Moreover, LD Score regression based on summary 
statistics generally yield bigger SEs than that from REML (GCTA) based on individual 
genotypes (Bulik-Sullivan et al. 2015a). Together these suggest that an even larger sample 
size is required for LD Score regression as compared to REML (GCTA) to achieve 
comparable power when estimating rg. The impact of sample size is evident in our results. 
We saw a larger SE around its rg estimate for cancer subtypes of smaller number of cases 
(ER-negative breast cancer, aggressive prostate cancer, lung adenocarcinoma, and lung 
squamous cell carcinoma) relative to their overall cancer type counterparts (Table 1&2). The 
two cancer types that have the smallest sample size in our datasets—colon cancer GWAS 
with less than 10,000 and ovarian cancer GWAS with less than 15,000 individuals—were 
found to have a non-significant rg surrounded by a wide confidence interval, but the effect 
size of rg between colon cancer and AD is in fact not negligible. Increasing sample size 
would likely reduce SEs and increase statistical power to detect a true genetic correlation.
In conclusion, we identified significant genetic correlations between AD and certain types of 
cancer that indicate the presence of shared genetic variants and disease mechanisms between 
the two diseases. To the best of our knowledge, this is the first investigation of genome-wide 
association between AD and cancer using GWAS summary statistics coming from large 
scale studies. Our functional category analysis suggests that regulation of gene expression in 
relation to enhancer activity might play an important role in this shared heritability. 
Integration with gene expression data or eQTL studies in specific tissues is needed to better 
define the overlapping biological pathways, find genes and regions on the genome to be 
targeted for functional studies, and connect the missing dots from genetic comorbidity 
discovered using SNP data to the association observed at the levels of gene expression and 
phenotype. We anticipate incorporating our current findings of a quantified and 
characterized genetic relationship between AD and a range of cancer types into functional 
studies that can generate a better understanding of the pathophysiology of AD and cancer 
and provide insights into novel therapeutic possibilities for both diseases.
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Fig. 1. Genetic correlation between AD and each cancer type, estimated by cross-trait LD score 
regression
Error bars are displayed as point estimate ± SE; “**” denotes p-value for genetic correlation 
< 0.05; “Any cancer” category includes all colon cancer, breast cancer (overall), prostate 
cancer (overall), ovarian cancer (overall), and lung cancer (overall).
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Figure 2. Annotation-specific genetic correlations (± SE) between AD and each cancer type
“*” denotes p-value for genetic correlation < 0.05; functional categories on the x-axis were 
ordered based on its size, from the smallest (left) to the largest (right)
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Fig. 3. Relationship between SNP, gene expression, and observed phenotype(s)
(a) A possible scenario where an inverse correlation of gene expression effects (Ibanez et al. 
2014) and a positive correlation of SNP effects between AD and cancer can be observed
(b) Possible causal pathways for the relationship between the three components if 
correlation exists between either two components. From up to down: causal effect of SNP on 
phenotype mediated through gene expression; gene expression reacts to phenotypic change 
due to SNP effect; pleiotropic effect of SNP on both gene expression and phenotype
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